Publicly funded Immunization Programs in Canada - Routine Schedule for Infants and Children (including special programs and catch-up programs)

Province/ Territory	DTaP-IPV-Hib	DTaP-IPV	Td, Tdap or Td-IPV	HB	MMR	Var	Men-C	Menactra- (Groups A, C, Y, W-135 conjugate)	Pneu-C-7	Pneu- C-10 Synflorix	Inf	HPV
NACI recom- mendation	2, 4, 6, 18 mths	4-6 yrs	14-16 yrs	Infancy (3 doses) OR Pre-teen/teen (2-3 doses)	12 mths AND 18 mths OR 4-6 yrs	12-18 mths (1 dose)	Infancy (1-4 doses)¹ AND Pre-teen (1 dose)¹	Pre-teen (1 dose) ¹	2, 4, 6, 12-15 mths		6-23 mths (1-2 doses)	Females 9-13 yrs (3 doses at 0, 2, 6 mths)²
BC	2, 4, 6 (DTaP- HB-IPV-Hib); 18 mths (DTaP-IPV-Hib)	4-6 yrs	Tdap, Gr. 9	2, 4, 6 mths (DTaP- HB-IPV-Hib); Catch-up Gr. 6 (HB)	12, 18 mths	12 mths, Catch-up 4-6 yrs, Gr. 6	2, 12 mths; Gr. 6		Healthy children: 2, 4, 12 mths		6-23 mths	Started in Sept 2008: Females Gr. 6, 9
AB	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	Gr. 5	12 mths, 4-6 yrs	12 mths	2, 4, 12 mths		2, 4, 6, 18 mths		6-59 mths	Started in Sept 2008: Females Gr. 5; Catch-up Gr. 9 from 2009 to 2012
SK	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 8	Gr. 6	12, 18 mths; Catch up Gr. 8, 12	12 mths; Catch-up Gr. 6	12 mths, 4-6 yrs; Catch up Gr. 6		2, 4, 6, 18 mths, at risk children up to 59 mths		6-23 mths	Started in Sept 2008: Females Gr. 6; Catch-up Gr. 7 for one year only
MB	2, 4, 6, 18 mths	4-6 yrs	Tdap, 14-16 yrs	Gr. 4	12 mths, 4-6 yrs	12 mths; Catch-up 4-6 yrs, Gr. 4	12 mths, Gr. 4		2, 4, 6, 18 mths		6-23 mths	Started in Sept 2008: Females Gr. 6
ON	2, 4, 6, 18 mths	4-6 yrs	Tdap, 14-16 yrs	Gr. 7 (2 doses)	12, 18 mths	15 mths	12 mths; Catch up Gr. 7, 15-19 yrs	Starting in Sept 2009 Gr. 7	2, 4, 6, 15 mths		≥ 6 mths	Started in Sept 2007: Females Gr. 8
QC	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	Gr. 4	12, 18 mths	12 mths; Catch-up 4-6 yrs, Gr. 4, 3rd year of high school, all non-immune individuals	12 mths; Catch-up < 18 yrs		2, 4, 12 mths; ; Catch-up < 5 yrs	2, 4, 12 mths (June 2009)	6-23 mths	Started in Sept 2008: Females Gr. 4, offered to 9-17 yr olds; Catch-up 3rd year of high school until 2013
NB	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9; Catch-up Gr. 6 (2006-2009)	0, 2, 6 mths	12, 18 mths, Catch-up Gr. 12 (2007-2014)	12 mths	12 mths	Gr. 9	2, 4, 6, 18 mths		6-23 mths	Started in Sept 2008: Females Gr. 7; Catch-up Gr. 8 (2008-2009)
NS	2, 4, 6, 18 mths	4-6 yrs	Tdap, 14-16 yrs, Gr. 7	Program on hold until 2010	12 mths, 4-6 yrs	12 mths; Catch-up 1-6 yrs;	12 mths; Catch-up Gr. 7, 14-16 yrs		2, 4, 6, 18 mths		6-23 mths	Started in Sept 2007: Females Gr. 7
PE	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	2, 4, 15 mths	15, 18 mths	12 mths	12 mths	Gr. 9	2, 4, 6, 18 mths			Started in Sept 2007: Females Gr. 6
NL	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	Gr. 4 (3 doses)	12, 18 mths	12 mths; Catch-up 4-6 yrs	12 mths; Catch-up Gr. 4, Gr. 9	Gr. 4 2009-12, Used in outbreak situations	2, 4, 6, 18 mths		6-23 mths	Started in Sept 2007, Sept 2008: Females Gr. 6, 9
NT	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	0, 1, 6 mths	12, 18 mths, Post secondary students attending schools outside NT	12 mths; Catch-up <5 yrs	2, 12 mths; Catch-up <5 yrs, Gr. 9	Post secondary students attending schools outside NT	2, 4, 6, 18 mths		6-23 mths	Starting in Sept 2009, Females Gr.4; Catch-up Gr.9-12 2009-14
YT	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	2, 4, 12 mths; Catch-up ≥ 19 yrs	12, 18 mths	12 mths	2, 12 mths; Catch-up Gr. 9, post-secondary students not previously immunized		2, 4, 6, 18 mths		> 6mths	Starting in fall 2009, Females Gr. 6 (3 doses); Catch-up Gr. 7, 8
NU	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	0, 1, 9 mths	12, 18 mths, Gr. 12	15 mths	12 mths; Catch-up 14-16 yrs		2, 4, 6, 15 mths		≥ 6 mths	Starting in winter 2009, Females Gr.6
Original Source: Canadian Nursing Coalition on Immunization, 2009 Updated: 2009-09-25
Legend: DTaP: Diphtheria, Tetanus, Acellular Pertussis HB: Hepatitis B Hib: Haemophilus Influenzae Tybe b HPV: Human Papillomavirus Inf: Influenza IPV: Inactivated Polio Men C: Meningococcal conjugate MMR: Measles, Mumps, Rubella Pneu-C-7, Pneu-C-10: Pneumococcal conjugate, 7, and 10 valent Var: Varicella
Recommended use: 1. If meningococcal C conjugate vaccine is given to infants < 12 months of age, a booster dose should be given in the second year of life (from 12 to 23 months of age). The early adolescent dose may be given using either meningococcal C conjugate (Men-C) vaccine or quadrivalent conjugate meningococcal vaccine (Men-C-ACYW) depending on the burden of illness from serogroups A, Y and W135 and the age distribution of cases by serogroup in individual Provinces / territories. Updated Invasive Meningococcal Vaccine Conjugate Recommendations can be found at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09pdf/acs-dcc-3.pdf 2. The HPV vaccine is recommended for females between 9 and 13 years of age, as this is before the onset of sexual intercourse for most females in Canada, and the efficacy would be greatest. Females between the ages of 14 and 26 years would benefit from the HPV vaccine, even if they are already sexually active, as they may not yet have HPV infection and are very unlikely to have been infected with all four HPV types in the vaccine. Females between the ages of 14 and 26 years who have had previous Pap abnormalities, including cervical cancer, or have had genital warts or known HPV infection would still benefit from the HPV vaccine.